

References

1. Amosova E.N. Internal medicine: Medicine, 2008.1064 p.
2. Armour R, Zhou L. Outcomes of statin myopathy after statin withdrawal. *J Clin Neuromuscul Dis* 2013;14(3):103–9.
3. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, Wilson PWF, D'Agostino RB. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study – Implications for LDL Management. *J Clin Lipidol* 2007;1(6):583–92.
4. Deanfield JE, Sellier P, Thaulow E, Bultas J, Yunis C, Shi H, Buch J, Beckerman B. Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? *Eur Heart J* 2010;31(21):2650–9.
5. Eindhoven JA, Onuma Y, Oemrawsingh RM, Daemen J, van Nierop JW, de Jaegere PP, Boersma E, Serruys PW, van Domburg RT. Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study. *Euro Intervention* 2012;7 (12):1420–7.
6. Franc S, Dejager S, Bruckert E. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. *Cardiovasc Drugs Ther* 2003;17 (5–6):459–65.
7. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. *Ann Intern Med* 2006;145 (7):520–30.
8. Heidrich J, Behrens T, Raspe F, Keil U. Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany. *Eur J Cardiovasc Prev Rehabil* 2005;12 (6):521–9.
9. McKenney JM, Brown WV, Cohen JD, Cahill E. The National Lipid Association surveys of consumers, physicians, and pharmacists regarding an over-the-counter statin in the United States: is this a good idea? *Am J Cardiol* 2004;94 (9A):16F–21F.
10. Ong AT, Serruys PW, Aoki J, Hoyer A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Regar E, van der Ent M, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT. The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. *J Am Coll Cardiol* 2005;45 (7):1135–41.
11. Pearson TA. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. *Am J Cardiol* 2004;94(9A):4F-8F.
12. Reiner Z, Catapano AL, de Backer G, Graham I, Taskinen M-R, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 2011;32:1769–818.
13. Richards MK, Blumenfeld S, Lyon RA. Managed care market perspectives on the over-the-counter availability of statins. *J Manag Care Pharm* 2004;10 (6):543–50.

14. Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. *Am Heart J* 2011;161(5):993–9.
15. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. *Curr Opin Pharmacol* 2008;8(3):333–8.
16. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2011;1:CD004816.
17. Topol EJ. *The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care.* New York Basic Books. 2012:304.
18. Zahno A, Brecht K, Bodmer M, Bur D, Tsakiris DA, Krähenbühl S. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. *Br J Pharmacol* 2010;161(2):393–404.